When appetite changes, it is easy for the scale to become the only thing anyone discusses. Meals, strength, energy, and everyday function deserve attention too, especially as you get older.
This is a guide to questions for your care team, not a protein prescription or exercise program. Your health conditions, eating pattern, and physical abilities should shape the plan.
Ask how treatment will support nourishment and everyday function, as well as the condition being treated.
Start with what eating looks like now
Tell your clinician or dietitian about a normal day of meals, foods you enjoy, and any barriers such as nausea, dental problems, cost, or difficulty shopping. A plan that ignores those details can be hard to follow even when its nutrition advice sounds reasonable.
A joint clinical advisory from major nutrition and obesity organizations emphasizes nutritional assessment and individualized support during GLP-1 therapy. It is broader guidance, not a trial proving a particular diet for every tirzepatide user.
Sources: Joint clinical advisory on nutrition during GLP-1 therapy
Protein and strength belong together
The advisory discusses adequate protein and resistance exercise as part of preserving muscle and function during weight loss. It also explains that simply increasing protein may be insufficient without an appropriate strength-training component.
Ask what is suitable for your circumstances, including kidney disease, mobility limitations, or a history of falls. A dietitian or qualified rehabilitation professional can help translate general advice into meals and movement that are realistic for you. Avoid copying a stranger’s gram target or workout because you use the same medicine.
Sources: Joint clinical advisory on nutrition during GLP-1 therapy
Do not turn persistent symptoms into a nutrition challenge
If vomiting, diarrhea, or significant abdominal pain is making it difficult to eat or drink, contact your clinical team. Approved tirzepatide labels describe serious gastrointestinal problems and dehydration-related kidney risks. A supplement does not replace evaluation of those symptoms.
Our side-effect guide explains selected warning signs. Ask your clinician what to track between visits and how quickly to call when food or fluids become difficult. Do not adjust the medicine using a general meal-planning article.
Sources: Lilly: Zepbound prescribing information · Lilly: Mounjaro prescribing information
Decide how you will notice useful progress
A follow-up conversation can include how you manage stairs, shopping, meals, and other activities that matter to you. Those observations help communicate your experience; they are not a substitute for the clinical measurements your prescriber recommends.
The first-visit fieldnote can help you raise these priorities early. If you are comparing services, read the Mochi review for questions about included nutrition support and the cost guide for checking what support actually costs.
Sources: Joint clinical advisory on nutrition during GLP-1 therapy · NIDDK: Prescription medicines for overweight and obesity · Mochi Health: Public care and pricing FAQs
The source shelf
- Joint clinical advisory on nutrition during GLP-1 therapy
Joint professional advisory; general nutritional support, not proof of a specific compounded product or a personal meal plan.
- Lilly: Zepbound prescribing information
Current approved-product label, revised August 2026; does not establish equivalence of compounded preparations.
- Lilly: Mounjaro prescribing information
Product-specific diabetes indications and safety information. Not an interchangeable label for compounded tirzepatide.
- NIDDK: Prescription medicines for overweight and obesity
Chronic weight-management decisions and ongoing lifestyle care.
- Mochi Health: Public care and pricing FAQs
Membership, medication and insurance pathways must be distinguished.
